Market Closed -
Nasdaq
21:00:00 17/05/2024 BST
|
5-day change
|
1st Jan Change
|
8.43
USD
|
-1.75%
|
|
-2.09%
|
+110.75%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
182
|
766.9
|
457.9
|
338.3
|
106.8
|
121.7
|
Enterprise Value (EV)
1 |
166.1
|
52.29
|
220.6
|
101.4
|
-110.6
|
-78.28
|
P/E ratio
|
-8.6
x
|
1.29
x
|
-43
x
|
-19.2
x
|
-3.25
x
|
-4.94
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
10,408,178
x
|
18,394,276
x
|
26,643,856
x
|
-
|
EV / Revenue
|
-
|
-
|
5,013,128
x
|
5,510,564
x
|
-27,590,059
x
|
-
|
EV / EBITDA
|
-8.95
x
|
-1.81
x
|
-13.8
x
|
-4.52
x
|
3.47
x
|
2.19
x
|
EV / FCF
|
-19.3
x
|
1.22
x
|
-1.54
x
|
1.54
x
|
17.5
x
|
4.86
x
|
FCF Yield
|
-5.19%
|
81.8%
|
-65%
|
65.1%
|
5.72%
|
20.6%
|
Price to Book
|
4.41
x
|
1.03
x
|
1.32
x
|
1.26
x
|
0.44
x
|
0.56
x
|
Nbr of stocks (in thousands)
|
35,820
|
41,087
|
29,261
|
30,399
|
30,439
|
30,437
|
Reference price
2 |
5.080
|
18.66
|
15.65
|
11.13
|
3.510
|
4.000
|
Announcement Date
|
14/03/19
|
16/03/20
|
16/03/21
|
15/03/22
|
15/03/23
|
15/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
44
|
18.39
|
4.01
|
-
|
EBITDA
1 |
-18.56
|
-28.87
|
-16.04
|
-22.43
|
-31.88
|
-35.77
|
EBIT
1 |
-20.99
|
-31.23
|
-18.28
|
-25.08
|
-34.49
|
-37.51
|
Operating Margin
|
-
|
-
|
-41.54%
|
-136.36%
|
-860.1%
|
-
|
Earnings before Tax (EBT)
1 |
-21.14
|
718.5
|
-12.83
|
-25.46
|
-33.59
|
-24.31
|
Net income
1 |
-21.14
|
668.6
|
-11.22
|
-17.41
|
-32.9
|
-24.56
|
Net margin
|
-
|
-
|
-25.5%
|
-94.67%
|
-820.45%
|
-
|
EPS
2 |
-0.5904
|
14.44
|
-0.3640
|
-0.5800
|
-1.081
|
-0.8100
|
Free Cash Flow
1 |
-8.627
|
42.76
|
-143.4
|
66
|
-6.33
|
-16.1
|
FCF margin
|
-
|
-
|
-325.88%
|
358.82%
|
-157.86%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
6.4%
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
14/03/19
|
16/03/20
|
16/03/21
|
15/03/22
|
15/03/23
|
15/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
15.8
|
715
|
237
|
237
|
217
|
200
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-8.63
|
42.8
|
-143
|
66
|
-6.33
|
-16.1
|
ROE (net income / shareholders' equity)
|
-41.6%
|
168%
|
-2.03%
|
-5.64%
|
-12.9%
|
-10.7%
|
ROA (Net income/ Total Assets)
|
-24.5%
|
-4.53%
|
-1.95%
|
-4.99%
|
-8.27%
|
-9.92%
|
Assets
1 |
86.44
|
-14,750
|
575
|
349.3
|
397.8
|
247.6
|
Book Value Per Share
2 |
1.150
|
18.20
|
11.90
|
8.850
|
7.900
|
7.190
|
Cash Flow per Share
2 |
0.4400
|
17.20
|
8.100
|
7.790
|
5.170
|
6.570
|
Capex
1 |
0.12
|
0.2
|
3.73
|
3.53
|
0.59
|
0.36
|
Capex / Sales
|
-
|
-
|
8.47%
|
19.16%
|
14.59%
|
-
|
Announcement Date
|
14/03/19
|
16/03/20
|
16/03/21
|
15/03/22
|
15/03/23
|
15/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +110.75% | 261M | | +9.42% | 114B | | +11.84% | 104B | | -14.15% | 22.41B | | -1.05% | 22.28B | | -5.29% | 19.07B | | -38.29% | 18B | | -4.16% | 17.89B | | +7.99% | 14.28B | | +36.24% | 12.55B |
Bio Therapeutic Drugs
|